The group II metabotropic glutamate receptor agonist LY354740 and the D2 receptor antagonist haloperidol reduce locomotor hyperactivity but fail to rescue spatial working memory in GluA1 knockout mice. by Burner,  T. et al.
Durham Research Online
Deposited in DRO:
08 March 2017
Version of attached ﬁle:
Published Version
Peer-review status of attached ﬁle:
Peer-reviewed
Citation for published item:
Burner, T. and Bygrave, A. and Chen, J. and Fernando, A. and Jackson, S. and Barkus, C. and Sprengel, R.
and Seeburg, P.H. and Harrison, P. J. and Gilmour, G. and Bannerman, D.M. and Sanderson, D.J. (2017)
'The group II metabotropic glutamate receptor agonist LY354740 and the D2 receptor antagonist haloperidol
reduce locomotor hyperactivity but fail to rescue spatial working memory in GluA1 knockout mice.',
European journal of neuroscience. .
Further information on publisher's website:
https://doi.org/10.1111/ejn.13539
Publisher's copyright statement:
c© 2017 The Authors. European Journal of Neuroscience published by Federation of European Neuroscience Societies
and John Wiley Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution
License, which permits use, distribution and reproductionin any medium, provided the original work is properly cited.
Additional information:
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for
personal research or study, educational, or not-for-proﬁt purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in DRO
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full DRO policy for further details.
Durham University Library, Stockton Road, Durham DH1 3LY, United Kingdom
Tel : +44 (0)191 334 3042 | Fax : +44 (0)191 334 2971
http://dro.dur.ac.uk
The group II metabotropic glutamate receptor agonist
LY354740 and the D2 receptor antagonist haloperidol
reduce locomotor hyperactivity but fail to rescue spatial
working memory in GluA1 knockout mice
Thomas Boerner,1 Alexei M. Bygrave,1 Jingkai Chen,1 Anushka Fernando,1 Stephanie Jackson,1 Chris Barkus,1
Rolf Sprengel,2 Peter H. Seeburg,2 Paul J. Harrison,3 Gary Gilmour,4 David M. Bannerman1,* and
David J. Sanderson5,*
1Department of Experimental Psychology, University of Oxford, 9 South Parks, Oxford, OX1 3UD, UK
2Max Planck Research Group, Institute for Anatomy and Cell Biology, Heidelberg University, Heidelberg, Germany
3Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
4Lilly Centre for Cognitive Neuroscience, Discovery Biology, Lilly Research Centre, Lilly UK, Windlesham, Surrey, UK
5Department of Psychology, Durham University, Science Site, South Road, Durham, DH1 3LE, UK
Keywords: AMPA, Gria1, habituation, schizophrenia
Edited by Anthony Isles
Received 2 September 2016, revised 18 January 2017, accepted 7 February 2017
Abstract
Group II metabotropic glutamate receptor agonists have been suggested as potential anti-psychotics, at least in part, based on
the observation that the agonist LY354740 appeared to rescue the cognitive deficits caused by non-competitive N-methyl-D-aspar-
tate receptor (NMDAR) antagonists, including spatial working memory deficits in rodents. Here, we tested the ability of LY354740
to rescue spatial working memory performance in mice that lack the GluA1 subunit of the AMPA glutamate receptor, encoded by
Gria1, a gene recently implicated in schizophrenia by genome-wide association studies. We found that LY354740 failed to rescue
the spatial working memory deficit in Gria1/ mice during rewarded alternation performance in the T-maze. In contrast,
LY354740 did reduce the locomotor hyperactivity in these animals to a level that was similar to controls. A similar pattern was
found with the dopamine receptor antagonist haloperidol, with no amelioration of the spatial working memory deficit in Gria1/
mice, even though the same dose of haloperidol reduced their locomotor hyperactivity. These results with LY354740 contrast with
the rescue of spatial working memory in models of glutamatergic hypofunction using non-competitive NMDAR antagonists. Future
studies should determine whether group II mGluR agonists can rescue spatial working memory deficits with other NMDAR manip-
ulations, including genetic models and other pharmacological manipulations of NMDAR function.
Introduction
Group II metabotropic glutamate receptor agonists have been sug-
gested as potential anti-psychotics, and have been used in clinical
trials, albeit with mixed results (Patil et al., 2007; Kinon et al.,
2015). Interest in these compounds as anti-psychotics was initially
raised by the observation that group II mGluR agonists, such as
LY354740, were found to rescue the deﬁcit in spatial working mem-
ory seen following glutamatergic dysfunction with non-competitive
NMDAR antagonists, like phencyclidine (PCP) and MK-801, on the
T-maze rewarded alternation task in rats (Moghaddam & Adams,
1998; Blot et al., 2015), as well as reducing the locomotor hyperac-
tivity seen with both dopaminergic and glutamatergic challenges
(Moghaddam & Adams, 1998; Pehrson & Moghaddam, 2010).
These compounds were therefore attractive as they appeared to pro-
vide a way of restoring cognitive function in disorders like
schizophrenia, as well as ameliorating positive symptoms (Sendt
et al., 2012).
The underlying rationale for these studies was provided by the
inﬂuential glutamate hypothesis of schizophrenia, in which NMDAR
dysfunction plays a central role (Olney & Farber, 1995; Coyle,
1996), and has been supported by recent evidence that schizophrenia
genes impact on glutamatergic synapses (Harrison & Owen, 2003;
Moghaddam, 2003; Harrison & Weinberger, 2005; Harrison &
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West, 2006). Despite the focus on NMDARs, there is increasing
evidence that AMPARs, and in particular the GluA1 subunit (also
known as GluR-A or GluR1, and encoded by the gene Gria1), may
also contribute to the disorder (Barkus et al., 2014). Post-mortem
studies have suggested that GluA1 expression is decreased in the
hippocampus of patients with schizophrenia (e.g. Eastwood et al.,
1995) and, signiﬁcantly, recent large scale GWAS meta-analyses
have established genome-wide association to schizophrenia for the
Gria1 locus (Ripke et al., 2013; Schizophrenia Working Group of
the Psychiatric Genomics, 2014).
Mice in which the Gria1 gene has been deleted (Gria1/ mice)
show impaired hippocampal synaptic plasticity (Zamanillo et al.,
1999; Hoffman et al., 2002; Romberg et al., 2009; Erickson et al.,
2010). At the behavioural level, Gria1/ mice exhibit a number of
robust and reproducible phenotypes, including pronounced sponta-
neous locomotor hyperactivity in novel environments, although
activity levels are not elevated in the home cage (Bannerman et al.,
2004; Wiedholz et al., 2008; Procaccini et al., 2013; Maksimovic
et al., 2014). Gria1/ mice also exhibit a selective short-term
memory deﬁcit on hippocampus-dependent spatial working memory,
win-shift maze tasks, including T-maze rewarded alternation (Reisel
et al., 2002; Schmitt et al., 2003; Sanderson et al., 2007; Taylor
et al., 2011). We have shown previously that Gria1/ mice exhibit
impaired performance on this task, even after extensive training
(Reisel et al., 2002). In contrast, Gria1/ mice display normal
(Zamanillo et al., 1999; Reisel et al., 2002) or even, enhanced (Sch-
mitt et al., 2003; Sanderson et al., 2009) long-term spatial memory
performance. We have proposed that the selective deﬁcit in tests of
spatial working memory reﬂects a failure to express short-term
habituation to recently experienced stimuli (Sanderson & Banner-
man, 2012). This account is also able to explain other behavioural
effects found with GluA1 knockout using nonspatial stimuli (San-
derson et al., 2011a,b).
The group II mGluR agonist LY354740 has been shown to
reduce the locomotor hyperactivity in Gria1/ mice (Procaccini
et al., 2013). Therefore, in the present study we investigated if
LY354740 would rescue the spatial working memory deﬁcit in Gri-
a1/ mice, given its apparent pro-cognitive effects in other models
of glutamatergic hypofunction (Moghaddam & Adams, 1998; Blot
et al., 2015), and its effects on locomotor activity in Gria1/ mice
(Procaccini et al., 2013). Furthermore, Wiedholz et al. (2008)
demonstrated that a 0.3 mg/kg dose of haloperidol (Mohn et al.,
1999), a dopamine receptor antagonist and widely used antipsy-
chotic drug, also reduces the locomotor hyperactivity exhibited by
Gria1/ mice. Therefore, for comparison, we also investigated
whether this same dose of haloperidol that reduces the locomotor
hyperactivity seen in Gria1/ mice would rescue spatial short-
term/working memory performance in these mice on a T-maze
rewarded alternation task.
Methods
Subjects
The experiments used littermate, aged-matched wild-type (WT) and
Gria1/ mice bred in the Department of Experimental Psychology
at the University of Oxford (see Zamanillo et al. (1999) for details
of genetic construction, breeding and subsequent genotyping). In
brief, the mice were derived from 129S2/SvHsd and C57BL/
6JolaHsd background strains, and then backcrossed to C57BL/
6JolaHsd. Experimental cohorts were generated by crossing male
and female heterozygous Gria1+/ mice. The mice were
6–14 months old at the start of testing. Mice were housed in cage
groups of up to 6, in a temperature and humidity controlled vivar-
ium. The animals were maintained on a 12 h light-dark cycle
(lights on; 07.00 – 19.00). All procedures were in accordance with
the United Kingdom Animals Scientiﬁc Procedures Act (1986);
under the UK Home Ofﬁce project licenses PPL 30/2561 and PPL
30/3068.
Drugs
In Experiments 1 and 2, LY354740 (provided by Eli Lilly U.K.)
was made up in sterile water (Norbrook) at a concentration of either
1.5 or 3 mg/mL. The pH was adjusted to approximately pH 7 by
spiking with small aliquots of 1M NaOH. All injections were given
intraperitoneally at doses of either 15 or 30 mg/kg/10 mL. These
doses have been used in prior studies examining the effects of group
II mGluR agonists on locomotor hyperactivity in Gria1/ mice
(see Procaccini et al., 2013). In Experiments 3 and 4, haloperidol
(0.3 mg/kg/10 mlL/; Janssen-Cilag Ltd, High Wycombe, UK) or
saline injections were given intraperitoneally. The drug dose was
selected on the basis of the previous study by Wiedholz et al.
(2008), in which haloperidol was shown to reduce hyperactivity in
Gria1/ mice.
Experiment 1: The effect of the group II mGluR agonist
LY354740 on spatial short-term/working memory during
rewarded alternation testing in Gria1/ mice
We ﬁrst assessed the effects of LY354740 on spatial working mem-
ory performance during rewarded alternation testing in wild-type
and Gria1/ mice. Rewarded alternation (see Reisel et al., 2002;
Bannerman et al., 2003; Schmitt et al., 2004; Deacon & Rawlins,
2006; Taylor et al., 2011) was tested using a grey, elevated wooden
T-maze. This consisted of a start arm (47 9 10 cm) and two identi-
cal goal arms (35 9 10 cm), surrounded by a 10 cm high wall. A
metal food well (0.8 cm diameter, 0.6 cm high) was ﬁxed to the
end of each goal arm. Several days before the start of testing, mice
were reduced to 85% of their free-feeding weight, by receiving a
restricted diet, and familiarized to the T-maze, and to the sweetened,
condensed milk reward (condensed milk diluted with water using a
50 : 50 ratio).
Each trial consisted of a sample run and a choice run. On the
sample run a mouse was placed in the start arm, facing away from
the goal arms, and forced to enter either the left goal arm or right
goal arm (determined by blocking the entrance to the opposite goal
arm with a wooden block) to obtain a milk reward (0.1 mL). After
the sample run the block was removed and the mouse was placed
back in the start arm and allowed to choose to enter either the left
or right goal arm (free choice run). The mouse was rewarded for
choosing the previously unvisited arm (i.e., for alternating).
A choice was made once all four paws were inside a goal arm.
There was a minimal delay between the end of the sample run and
start of the choice run (< 5 s). This reﬂected the minimum amount
of time required for the experimenter to remove the animal from the
maze, remove the wooden block and then replace the mouse at the
beginning of the start arm. On sample runs mice were forced either
left or right according to a pseudorandom sequence in which there
were equal numbers of left and right forced runs per blocks of ten
trials, and no more than three consecutive sample runs to the same
goal arm. The inter-trial interval (i.e., the interval between the end
of a choice run and the next, subsequent sample run) was approxi-
mately 6–10 min.
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In Experiment 1A wild-type (female: N = 6; male: N = 5) and Gri-
a1/ mice (female: N = 7; male: N = 8; see Table 1) ﬁrst received
30 trials of drug-free testing (ﬁve trials per day for 6 days). Each ani-
mal was then tested on rewarded alternation following an injection of
either LY354740 (15 mg/kg) or vehicle. After injection animals were
returned to the home cage for 30 min before behavioural testing com-
menced. Each animal was given 10 trials of rewarded alternation in
the T-maze. Mice were given a maximum of 120 s to a complete a
trial. At least 24 h after the ﬁrst round of drug testing the animals were
re-tested in the absence of any drug treatment to ensure that there were
no long-term effects of the drug, and that the mice maintained a high
level of alternation performance (with three sessions of ﬁve trials per
day in Experiment 1A, and one session of 10 trials per day in Experi-
ments 1B and 1C). Twenty-four hours after this re-testing, mice
received a further 10 trials of rewarded alternation testing, but now
under the drug condition that they had not previously received (i.e.,
mice that had previously received LY354740 then received vehicle
injections, and vice versa for the remaining mice). The order of drug
exposure was counterbalanced within genotype and sex as far as pos-
sible given the numbers of mice. In all stages, the number of trials in
which the animal alternated, as well as time taken to run from the start
arm to the food well on the sample run (sample latency), and the time
taken to run from the start arm to making a choice (i.e., entering an
arm with all four paws) on the choice run (choice latency), were
recorded. Latencies were measured by the experimenter using a stop-
watch. The experimenter was blind to the genotype and drug alloca-
tions of the animals throughout testing.
In Experiment 1B, separate groups of male wild-type (N = 7) and
Gria1/ mice (N = 7) underwent the same procedure as Experi-
ment 1A but now they received either vehicle or a higher dose of
LY354740 (30 mg/kg; see Table 1). Subsequently, in Experiment
1C, to investigate the potential effects of increased proactive inter-
ference, the procedure used in Experiment 1B was repeated in the
same mice, using the same drug dose (30 mg/kg), but now using a
modiﬁed testing protocol in which the interval between trials (i.e.
the interval between the end of a choice run and the next, subse-
quent sample run) was reduced to 20 s (see Table 1). This proce-
dure more closely matches the behavioural paradigm used by
Moghaddam & Adams (1998) in which LY354740 reversed the
effects of the non-competitive NMDAR antagonist, phencyclidine.
Experiment 2: The effect of the group II mGluR agonist
LY354740 on spontaneous locomotor activity in Gria1/ mice
We next assessed the effects of LY354740 on spontaneous locomotor
activity in a novel environment in wild type and Gria1/ mice. In
Experiment 2A the mice that had previously been tested in Experi-
ment 1A were returned to a free feeding regime and then tested for
spontaneous locomotor activity (see Table 1) in clear plastic cages
(26 9 16 9 17 cm), containing clean sawdust (see Bannerman
et al., 2004). Activity levels were assessed by an array of infrared
photobeam sensors that covered the x and y axes of the cages (San
Diego Instruments). Immediately after an injection of either 15 mg/kg
LY354740 or vehicle mice were placed individually into test cages.
The beam breaks were recorded in eight bins of 15 min over a 2-h
session. After the ﬁrst round of locomotor testing (and following a
washout period of 7 days), mice were tested in the locomotor cages
with the vehicle/drug allocations reversed. In the second test mice
were allocated a cage that was different from the ﬁrst test. The order
of drug/vehicle injections was counterbalanced for sex and genotype
as far as possible given the number of mice per condition.
In Experiment 2B experimentally na€ıve wild-type (female: N = 6;
male: N = 6) and Gria1/ mice (female: N = 6; male: N = 5) that
had been maintained with ad libitum access to food were also tested
for locomotor activity using an identical protocol as in Experiment
2A, but now with vehicle and 30 mg/kg LY354740 (see Table 1).
Finally, in Experiment 2C the mice that had been previously used
in Experiments 1B and 1C were maintained on food restriction (to
match the conditions used for T-maze testing) and locomotor activ-
ity was assessed with either the 30 mg/kg dose of the drug or vehi-
cle as described above (see Table 1).
Experiment 3: The effect of haloperidol on spatial short-term/
working memory during rewarded alternation testing in Gria1/
mice
For comparison, we also investigated the effects of the anti-psycho-
tic, D2 receptor antagonist haloperidol on spatial working memory
performance in wild-type and knockout mice (see Table 1). Wild-
type (female: N = 6; male: N = 6) and Gria1/ mice (female:
N = 6; male: N = 6) were tested on rewarded alternation in a similar
manner as Experiment 1. Rewarded alternation testing started with a
Table 1. Details of experimental procedure, age and sex of mice, drug manipulation and dose, and feeding regime for Experiments 1–4
Procedure Age Sex Drug manipulation Feeding regime
Experiment 1A Rewarded alternation –
long inter-trial interval
12–14 months WT: female = 6, male = 5
Gria1/: female = 7, male = 8
LY35470 15 mg/kg
within-subjects
Food restriction
Experiment 1B Rewarded alternation –
long inter-trial interval
6–10 months WT: male = 7
Gria1/: male = 7
LY35470 30 mg/kg
within-subjects
Food restriction
Experiment 1C Rewarded alternation –
short inter-trial interval
Same mice as
Experiment 1B
Same mice as Experiment 1B LY35470 30 mg/kg
within-subjects
Food restriction
Experiment 2A Locomotor activity Same mice as
Experiment 1A
Same mice as Experiment 1A LY35470 15 mg/kg
within-subjects
Free-feeding
Experiment 2B Locomotor activity 9–12 months WT: female = 4, male = 6
Gria1/: female = 6, male = 5
LY35470 30 mg/kg
within-subjects
Free-feeding
Experiment 2C Locomotor activity Same mice as
Experiment 1B
and 1C
Same mice as Experiment 1B and 1C LY35470 30 mg/kg
within-subjects
Food restriction
Experiment 3 Rewarded alternation –
long inter-trial interval
9 months WT: female 6, male = 6
Gria1/: female = 6, male = 6
Haloperidol 0.3 mg/kg
within subjects
Food restriction
Experiment 4 Locomotor activity Same mice as
Experiment 3
Same mice as Experiment 3 Haloperidol 0.3 mg/kg
between-subjects
(genotype and sex was
balanced across
drug conditions)
Free-feeding
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preliminary training stage in the absence of any injections. Mice
received ﬁve trials per day for 6 days. Mice were then tested under
the effects of haloperidol or saline in a within-subjects design. In
the ﬁrst drug-testing run, half of the mice from each genotype were
treated with haloperidol and the remaining mice with saline. Mice
received 14 trials of rewarded alternation after injection. After this
stage, re-testing was carried out in the absence of haloperidol or sal-
ine, with mice receiving ﬁve trials per day for 2 days. In the second
drug-testing run, mice that were previously injected with saline were
now treated with haloperidol and vice-versa, and again they received
14 trials of rewarded alternation after injection. The order of
haloperidol/saline administration was counterbalanced across sex as
well as genotype. For the drug-testing runs, testing commenced
15 min after injection of haloperidol/saline. In contrast with Experi-
ment 1, the mice were allowed a maximum of 180 s to complete
each of the choice and sample runs. If this time limit was not met,
the trial was ended and considered void. Mice that failed to com-
plete at least 10 of the 14 trials when tested under the effects of
haloperidol were excluded from all analyses of rewarded alternation
performance. Consequently, analysis of the drug testing stages was
based on data from the ﬁrst 10 successfully completed trials per
session. The experimenter was blind to the genotype and drug
allocations of the animals throughout testing.
Experiment 4: The effect of haloperidol on spontaneous
locomotor activity in Gria1/ mice
Finally, the same mice as used previously in Experiment 3 were
tested for spontaneous locomotor activity with haloperidol or vehicle
(see Table 1). Although spontaneous locomotor activity was mea-
sured in a similar way to Experiment 2, the apparatus used was dif-
ferent. Speciﬁcally, mice were placed individually into novel
transparent plastic cages (26 9 16 9 17 cm) that were positioned
between two sensor panels, with two horizontal photocell beams
projecting perpendicularly across the long axis of each cage. The
number of beam breaks that each mouse made was recorded by a
computer in eight time bins of 15 min each. The session lasted for
2 h. Locomotor testing commenced after the completion of Experi-
ment 3. Mice were put back on a free-feeding regime 2 weeks
before locomotor testing began. Half of the Gria1/ mice and half
of the WT mice were injected with haloperidol, and the remaining
mice were injected with saline, before they were then immediately
placed into the activity cages for 2 h.
Statistical analyses
Data were analysed using multifactorial ANOVA, or t-tests for
between group comparisons. Interactions were analysed using simple
main effects analyses using the error term from the original ANOVA.
Data were assessed for normality using the Shapiro-Wilk test.
Analysis was conducted using SPSS software, version 20.
Results
Experiment 1A: The group II mGluR agonist LY354740
(15 mg/kg) had no effect on spatial working memory
performance in Gria1/ or WT mice
The performance of mice during the pre-drug training phase was
analysed using a 2 (genotype) by 2 (sex) ANOVA. As expected,
Gria1/ mice exhibited a clear spatial working memory impairment
during the initial pre-drug testing stage of the rewarded alternation
T-maze task (mean alternation: WT = 70.91%  3.24 SEM; Gri-
a1/ mice = 53.11%  1.80 SEM; F1,22 = 24.017 P < 0.001).
There was no main effect of sex (F < 1, P > 0.4) or genotype by
sex interaction (F < 1, P > 0.6).
The performance of mice during the drug-testing phase is shown
in Fig. 1a. A 15 mg/kg dose of LY354740 failed to rescue spatial
working memory performance in the knockout mice. During the
drug-testing phase one male Gria1/ mouse failed to complete any
runs when treated with LY354740, and therefore the data from this
mouse were excluded from further analyses. The performance of
mice was analysed using a 2 (genotype) by 2 (sex) by 2 (drug/sal-
ine) ANOVA. Gria1/ mice were still impaired compared to WT
mice (F1,21 = 4.74, P = 0.041) during the drug testing sessions.
There was no signiﬁcant effect of drug and drug did not signiﬁ-
cantly interact with genotype (both F values < 1, P > 0.9, see
Fig. 1a). There was also no signiﬁcant main effect of sex (F < 1,
P > 0.60) and sex did not interact with other factors (F values < 1,
P values > 0.30). The 15 mg/kg dose of the drug also had no effect
on the running latencies of the mice on either the sample (F < 1,
P > 0.30) or choice runs (F < 1 P > 0.70), and there was no signif-
icant interaction between drug and genotype (F < 1, P > 0.50).
However, Gria1/ mice took longer to complete both sample and
choice runs in this particular experiment (F values > 10.00, P val-
ues < 0.005, see Fig. 1a). There were no other signiﬁcant main
effects or interactions (P values > 0.10).
Experiment 1B: The group II mGluR agonist LY354740
(30 mg/kg) had no effect on spatial working memory
performance in Gria1/ and WT mice
We next investigated whether a higher dose of the group II mGluR
agonist (30 mg/kg) might rescue spatial working memory perfor-
mance. A separate cohort of experimentally na€ıve mice were trained
on the T-maze task as before. The results were analysed using a
similar analyses as Experiment 1A except the factor of sex was
omitted due to all mice being male. The Gria1/ mice were again
substantially impaired during the pre-drug testing phase (mean alter-
nation: WT = 80.95%  2.15 SEM; Gria1/ mice = 46.67%
 2.30 SEM; F1,12 = 118.72, P < 0.001).
The performance of mice during the drug-testing phase is shown
in Fig. 1b. The higher 30 mg/kg dose of LY354740 also failed to
rescue rewarded alternation performance in the knockout mice (main
effect of drug – F1,12 = 2.043, P = 0.178), and drug treatment did
not interact with genotype (F1,12 = 1.149, P = 0.305, see Fig. 1b).
The pronounced deﬁcit in the Gria1/ mice remained across the
drug test sessions (main effect of genotype, F1,12 = 24.608,
P < 0.001). There was a strong suggestion that the 30 mg/kg dose
prolonged running latencies in both the sample (F1,12 = 4.42,
P = 0.057) and choice runs (F1,12 = 5.07, = 0.044). On this occa-
sion the Gria1/ mice ran faster than WT mice, but the effect of
genotype failed to reach signiﬁcance (F1,12 values < 4.20, P val-
ues > 0.06). The interaction between drug and genotype also failed
to reach signiﬁcance (F1,12 values < 3.80, P values > 0.07).
Experiment 1C: The group II mGluR agonist LY354740
(30 mg/kg) had no effect on rewarded alternation testing with
a short inter-trial interval in Gria1/ and WT mice
Given the lack of effect of the group II mGluR agonist on spatial
working memory performance in Experiments 1A and 1B, the
T-maze testing paradigm was changed to more closely resemble that
used by Moghaddam & Adams (1998), in which LY354740 had
© 2017 The Authors. European Journal of Neuroscience published by Federation of European Neuroscience Societies and John Wiley & Sons Ltd
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been shown previously to ameliorate the effect of the non-competi-
tive NMDAR antagonist, PCP, on rewarded alternation. This was
achieved by reducing the inter-trial interval from 6-10 min to 20 s.
The pronounced spatial memory deﬁcit in the Gria1/ mice was
still evident with this short inter-trial interval during initial ‘pre-
drug’ testing (WT = 73.33%  4.24 SEM; Gria1/
mice = 49.52%  3.89 SEM; F1,12 = 17.16, P = 0.001). However,
LY354740 still failed to rescue memory performance when using
this modiﬁed paradigm during the drug test sessions. There was still
no signiﬁcant main effect of drug (F1,12 = 1.28, P = 0.28), and no
interaction between drug and genotype (F < 1, P > 0.30). There
was an overall main effect of genotype (F1,12 = 15.52, P = 0.002,
see Fig. 1c), reﬂecting the continued and persistent short-term/work-
ing memory deﬁcit in the knockout mice.
The 30 mg/kg dose of LY354740 did, nevertheless, result in sig-
niﬁcantly prolonged running latencies on the choice run
(F1,12 = 4.83, P = 0.048, see Fig. 1c). There was a similar pattern
of results for the sample run latencies but this failed to reach signiﬁ-
cance (F1,12 = 3.034, P = 0.107). The effect of drug did not signiﬁ-
cantly interact with genotype (F1,12 values < 2.60, P values > 0.10),
and there was no signiﬁcant main effect of genotype for running
latencies in this experiment (F1,12 values < 3.20, P values
≥ P 0.10).
Experiment 2: The group II mGluR agonist LY354740 reduced
spontaneous locomotor activity in wild-type and Gria1/ mice
We next determined whether LY354740 would affect the locomotor
hyperactivity in a novel environment in Gria1/ mice. The mGluR
agonist reduced activity levels in both wild-type and Gria1/ mice.
In Experiment 2A spontaneous locomotor activity was analysed
using a 2 (genotype) by 2 (sex) by 2 (drug) by 8 (time bin) ANOVA. It
was found that Gria1/ mice were hyperactive compared to WT
mice (F1,22 = 5.82, P = 0.025, see Fig. 2a). The 15 mg/kg dose of
LY354740 reduced locomotor activity (F1,22 = 5.24, P = 0.032), but
the effect of drug did not interact with genotype (F < 1, P > 0.6).
Activity declined over time bins (F7,154 = 15.74, P < 0.001) and the
effect of genotype signiﬁcantly interacted with time bin
(F7,154 = 2.32, P = 0.028), as did drug (F7,154 = 2.76, P = 0.01) and
sex (F7,154 = 2.74, = 0.01), with the decline in activity over time
being greater for male than female mice. There were no other signiﬁ-
cant main effects or interactions of factors (P values > 0.1).
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Fig. 1. Rewarded alternation performance in WT and Gria1/ mice treated with vehicle and LY354740 in Experiments 1A (panel a; LY354740 15 mg/kg: WT,
N = 11, Gria1/, N = 15), 1B (panel b; LY354740 30 mg/kg: WT, N = 7, Gria1/, N = 7) and 1C (panel c; LY354740 30 mg/kg: WT, N = 7, Gria1/,
N = 7). In Experiment 1A (panel a) mice were tested using an inter-trial interval of 6-10 min. This procedure was repeated in Experiment 1B (panel b), but
with a higher dose (30 mg/kg). In Experiment 1C (panel c) the same mice that were tested in Experiment 1B were tested again with the 30 mg/kg dose but the
inter-trial interval was 20 s. The left column shows the mean alternation. The dashed line indicates chance level performance. The middle and right columns
show the latencies for the sample run and choice run, respectively. Error bars indicate SEM.
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The results of Experiment 2B were analysed in the same manner
as for Experiment 2A. In Experiment 2B Gria1/ mice were again
hyperactive (F1,19 = 9.13, P = 0.007) and, not surprisingly, the
30 mg/kg dose of LY354740 substantially reduced activity
(F1,19 = 50.54, P < 0.001), but, as before, the effect of drug did not
signiﬁcantly interact with genotype (F1,19 = 2.70, P = 0.18, see
Fig. 2b). There was a three-way genotype, sex and drug interaction
(F1,19 = 5.45, P = 0.031). This interaction, however, reﬂected a fail-
ure to ﬁnd the usual signiﬁcant hyperactivity effect in male Gria1/
mice in the vehicle condition in this particular experiment. Once
again the effects of genotype, sex and drug each interacted with
time bin (F values > 2.80, P values < 0.05).
It is possible that the effect of LY354740 in successfully reducing
the locomotor hyperactivity in Gria1/ mice, but the lack of any
drug effect on spatial working memory performance, could reﬂect
the different motivational/hunger state of the mice in the two experi-
ments (food deprived for spatial working memory testing vs. ad libi-
tum food for locomotor testing). To investigate this possibility, we
assessed the effects of LY354740 on spontaneous locomotor activity
levels in wild-type and Gria1/ mice maintained under the same
food restriction schedule as used for spatial working memory testing.
The results of Experiment 2C were analysed in a similar manner to
Experiments 2A and 2B except that effect of sex was omitted due to
all mice being male. A 30 mg/kg dose of LY354740 again signiﬁ-
cantly reduced locomotor activity (F1,12 = 51.26, P < 0.001). Gria1
deletion resulted in pronounced hyperactivity (F1,12 = 38.80,
P < 0.001), and on this occasion the effect of drug signiﬁcantly
interacted with genotype (F1,12 = 11.30, P = 0.006, see Fig. 2c). The
interaction reﬂected the fact that the effect of drug was larger for Gri-
a1/ mice (F1,12 = 55.35, P < 0.001) than for WT mice
(F1,12 = 7.21, P = 0.02). There was also a signiﬁcant effect of time
bin (F7,84 = 15.55, P < 0.001) and signiﬁcant three-way interaction
of factors (F7,84 = 3.60, P = 0.002).
Experiment 3: Haloperidol had no effect on rewarded
alternation in Gria1/ or wild-type mice
For comparison with the LY354740 data, we also investigated the
effects of the anti-psychotic D2 receptor antagonist, haloperidol, on
spatial working memory performance in Gria1/ mice. Previously,
Wiedholz et al. (2008) have demonstrated that haloperidol (0.3 mg/kg)
reduces the locomotor hyperactivity exhibited by Gria1/ mice.
However, it is also important to note that haloperidol also decreased
activity levels in normal animals (Wiedholz et al., 2008). In addition,
in vivo chronoamperometric measurements showed retarded dopamine
clearance in the knockouts, consistent with the possibility of a hyper-
dopaminergic state. More recently, we have used fast-scan cyclic
voltammetry to directly demonstrate increased phasic dopamine tran-
sients in freely moving, behaving Gria1/ mice relative to wild-type
littermates (Boerner et al., in preparation). Therefore, there is evi-
dence for a hyper-dopaminergic phenotype in these animals, and the
D2 antagonist attenuates the locomotor hyperactivity in the knockouts.
We therefore investigated whether haloperidol would have any effect
on spatial working memory performance in Gria1/ mice.
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Five WT and three Gria1/ mice failed to complete at least 10
out of 14 trials of rewarded alternation when tested under the effects
of haloperidol and were thus removed from all analyses of rewarded
alternation, including the initial, drug-free testing stage (leaving WT,
N = 7 and Gria1/, N = 9). A two-tailed chi-square test demon-
strated that the proportions of mice excluded for each genotype did
not differ, v²(1) = 0.75, P = 0.39.
The results of the initial training prior to drug treatment were
analysed using a 2 (genotype) by 2 (sex) ANOVA. It was found that
Gria1/ mice were again signiﬁcantly impaired on the rewarded
alternation task (mean alternation = 52.59%  3.71 SEM) compared
to WT mice (mean alternation = 69.52%  4.79 SEM;
F1,12 = 10.31, P = 0.007). There was no signiﬁcant main effect of
sex on choice performance (F < 1, P > 0.3). Due to the lack of
effect of sex during the initial testing state the factor of sex was
removed from subsequent analyses.
Haloperidol treatment did not result in a signiﬁcant change in the
choice accuracy (percent correct choices) of either WT or Gria1/
mice (main effect of drug: F < 1, P > 0.7, see Fig. 3). As during
the initial drug-free testing, the effect of genotype on choice perfor-
mance was highly signiﬁcant, reﬂecting the pronounced short-term/
working memory impairment in the Gria1/ mice (F1,14 = 13.52,
P = 0.002). There was no signiﬁcant drug by genotype interaction
(F < 1, P > 0.3).
Haloperidol treatment did have a signiﬁcant effect on time taken
to traverse the maze. There was a signiﬁcant increase in both sample
run (effect of drug, F1,14 = 10.99, P = 0.005) and choice run laten-
cies (F1,14 = 19.78, P = 0.001, see Fig. 3). There was no signiﬁcant
effect of genotype on either sample (F < 1, P > 0.4) or choice
latencies (F < 1, P > 0.5). However, there was a signiﬁcant drug by
genotype interaction for choice latencies (F1,14 = 6.04, P = 0.028).
Simple main effects analysis revealed that haloperidol signiﬁcantly
prolonged choice latencies for the WT mice (F1,14 = 21.19,
P < 0.001), but not for Gria1/ mice (F1,14 = 2.27, P = 0.16).
The drug by genotype interaction for sample latencies was not sig-
niﬁcant (F < 1, P > 0.9).
Experiment 4: Haloperidol reduced spontaneous locomotor
activity in wild-type and Gria1/ mice
Finally, we revisited the effects of the D2 receptor antagonist on the
locomotor hyperactivity in Gria1/ mice. The results were anal-
ysed in a similar manner to Experiment 2 except that the factor of
sex was omitted due to the numbers of each sex within each geno-
type and drug allocation being small (N = 3). Haloperidol treatment
signiﬁcantly reduced spontaneous locomotor activity (main effect of
drug, F1,20 = 56.20, P < 0.001, see Fig. 4). There was also a signif-
icant main effect of genotype (F1,20 = 17.37, P < 0.001), and a sig-
niﬁcant genotype by time bin interaction (F7,140 = 2.79, P < 0.05),
reﬂecting the pronounced hyperactivity in the Gria1/ mice. There
was also a drug by time bin interaction (F1,140 = 7.38, P < 0.001)
and a signiﬁcant genotype by drug interaction (F1,20 = 10.74,
P = 0.004). Simple main effects analysis showed that while saline
treated Gria1/ mice displayed signiﬁcant novelty-induced hyper-
locomotion compared to saline treated WT mice (F1,20 = 27.72,
P < 0.001), there was no signiﬁcant difference in novelty-induced
locomotor activity between haloperidol treated Gria1/ and WT
mice (F < 1, P > 0.5). Furthermore, simple main effects analysis
also showed that haloperidol signiﬁcantly reduced activity levels in
both WT (F1,20 = 8.90, P = 0.007) and Gria1
/ mice
(F1,20 = 58.05, P < 0.001). There was no signiﬁcant three-way
interaction of factors (F7,150 < 1, P = 0.55).
Acquisition of rewarded alternation performance in
Experiments 1a, 1b and 3
An additional analysis of acquisition of rewarded alternation perfor-
mance, pooled across experiments 1a, 1b 3, in which mice were
experimentally na€ıve at the start of training, showed that WT mice
started substantially above chance (ﬁrst 10 trials, mean = 72.00%
correct  2.15 SEM, t24 = 6.84, P < 0.001, chance = 50%). This is
consistent with other demonstrations that mice spontaneously alter-
nate rather than actually acquiring the alternation behaviour over
training (see Sanderson & Bannerman, 2012, for a discussion of
how alternation performance reﬂects short-term habituation rather
than acquisition of an alternation rule). In contrast, Gria1/ mice
failed to perform above chance (ﬁrst 10 trials, mean = 50.32% cor-
rect  3.21 SEM, t30 < 1, P > 0.80). Furthermore, both genotypes
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did not signiﬁcantly improve over subsequent blocks of trials (sec-
ond block of 10 trials: WT mean = 73.60% correct  2.51 SEM,
Gria1/ mean = 50.32% correct  2.64 SEM; third block of 10
trials: WT mean = 74.40% correct  3.32 SEM, Gria1/
mean = 53.87% correct  2.35 SEM; effect of block: F < 1,
P > 0.40; block by genotype interaction: F < 1, P > 0.80; effect of
genotype (F2,54 = 71.27, P < 0.001).
Discussion
The group II mGluR agonist, LY354740, reduced locomotor activity
levels in both wild-type and Gria1/ mice but, notably, it did not res-
cue spatial short-term/working memory performance in the knockout
animals, regardless of sex, during testing on the T-maze rewarded
alternation task. Similarly, we found that the dopamine D2 receptor
antagonist haloperidol reduced the locomotor hyperactivity observed
in Gria1/ mice when they were placed in a novel environment, but
the drug had no effect on choice accuracy performance levels during
spatial short-term/working memory testing in either knockout mice or
controls, despite again producing clear motoric effects on the T-maze.
Group II mGluR agonist LY354740 fails to rescue short-term
memory performance in a genetic mouse model of
glutamatergic hypofunction
The group II mGluR agonist LY354740 had no effect on spatial
working/short-term memory performance during T-maze rewarded
alternation testing in Gria1/ mice, indicating an inability to rescue
cognitive performance in a schizophrenia-relevant genetically modi-
ﬁed mouse model of glutamatergic dysfunction. Neither 15 nor
30 mg/kg doses of the drug had any effect on choice accuracy,
despite both doses resulting in clear reductions in locomotor activity
levels in both genotypes. Therefore, these drug doses were not with-
out effect. There were clear reductions in locomotor activity that
were not accompanied by any rescue of spatial short-term memory
processes. The lack of any rescue effect in the Gria1/ mice is
unlikely to be due to any negative performance effects of
LY354740 masking any positive effects of the drug on memory per-
formance, as the drug was also without any signiﬁcant effect in the
wild-type controls.
The failure of a group II mGluR agonist to rescue the spatial
working memory deﬁcit in a genetic model of glutamatergic hypo-
function (Gria1/ mice), stands in contrast with the successful res-
cue of the deﬁcit with pharmacological models of glutamatergic
hypofunction, for example with non-competitive NMDAR antago-
nists such as phencyclidine or MK801 (Moghaddam & Adams,
1998; Blot et al., 2015). There are several overt differences between
these models (genetic vs. pharmacological; AMPARs vs. NMDARs;
constitutive knockout throughout the lifetime of the animal vs. acute
drug administration; receptor subunit ablation vs. use-dependent
channel blockade), many, or all, of which could contribute to the
different outcomes with mGluR agonists. Further studies, such as
assessment of the effects of LY354740 on spatial working memory
deﬁcits in genetic models of NMDAR hypofunction (e.g., Niewoeh-
ner et al., 2007; Bannerman et al., 2008; Korotkova et al., 2010),
would shed further light on this issue.
Indeed, it would seem important to assess further the generality
of the effects of group II mGluR agonists on spatial working mem-
ory performance in other models of glutamatergic dysfunction and,
speciﬁcally, NMDAR hypofunction. It is potentially of note that
both of the published reports involve non-competitive, NMDAR
channel blockers (PCP or MK-801). These drugs exhibit a use-
dependent blockade of the NMDAR channel which reﬂects the fact
that a certain amount of glutamatergic activity is required in order
to open the NMDAR channels and allow the blockers access to their
binding sites. It is possible that the group II mGluR agonists, which
are known to reduce glutamate release through their action on presy-
naptic autoreceptors, could indirectly result in less NMDAR channel
openings and thus less opportunity for the NMDAR antagonists to
access their binding sites. This could reduce the effectiveness of
these non-competitive NMDAR antagonists in the presence of drugs
like LY354740. Interestingly, one might make the opposite predic-
tion for competitive antagonists like AP5 or CPP, where any reduc-
tion in pre-synaptic glutamate release caused by a group II mGluR
agonist might actually make the competitive antagonists more efﬁca-
cious as they will have less glutamate to compete with for access to
receptor binding sites. Either way, it would be desirable to deter-
mine whether group II mGluR agonists like LY354740 can rescue
spatial working memory deﬁcits with other NMDAR manipulations,
including both genetic models (Nakazawa et al., 2003; Niewoehner
et al., 2007; Korotkova et al., 2010) and other pharmacological
manipulations of NMDAR function such as competitive antagonists
(McHugh et al., 2008). This could be of particular relevance for
judging the clinical applicability of previous ﬁndings.
Haloperidol does not affect spatial short-term/working memory
The spatial short-term/working memory performance of both wild-
type and Gria1/ mice, in terms of choice accuracy on the T-maze
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rewarded alternation task, was also unaffected by haloperidol treat-
ment, even despite the clear motoric effects of the drug seen during
testing. The absence of a haloperidol effect on T-maze choice accu-
racy in normal animals has been shown previously (Aultman &
Moghaddam, 2001), and was not because the dose of the drug was
ineffective in the present study. The same dose of haloperidol had a
marked effect on locomotor activity levels in both genotypes in the
photocell activity cages, which replicated the previous study by
Wiedholz et al. (2008). Furthermore, the drug also had clear motoric
effects during the T-maze task itself. Haloperidol prolonged the run-
ning latencies of the mice (on both the sample and choice runs),
despite having no effect on memory performance. This led to some
animals failing to complete the trials in the allotted time and ‘timing
out’, although it is important to note that this effect was equivalent
for both genotypes. We cannot rule out the possibility that a higher
dose of haloperidol may have an effect on spatial short-term/work-
ing memory but it is also worth noting that any further increase in
the dose of the dopamine receptor antagonist used is likely to have
resulted in the animals failing to run and perform the task. Indeed,
as mentioned above, even at the dose of 0.3 mg/kg used in the pre-
sent study, ﬁve wild-type and three Gria1/ mice failed to com-
plete the experiment and had to be excluded from the study. There
is the distinct possibility that at higher doses the experiment would
prove unworkable. Nevertheless, the present study clearly shows that
haloperidol has motoric effects in both wild-type and Gria1/
mice, without having any effect on spatial short-term/working
memory.
In theory, it is also conceivable that a lower dose of haloperidol
could have a beneﬁcial effect on spatial short-term memory perfor-
mance in Gria1/ mice, and that the 0.3 mg/kg dose of haloperidol
that we used was too high, resulting in non-mnemonic effects that
were detrimental to performance, thus masking any positive effects
that the drug might have had on memory in the knockouts. In other
words, it is possible that haloperidol could rescue short-term mem-
ory function in GluA1 knockout mice but the motoric effects of the
drug prevent that rescue from being expressed at the behavioural
level in these animals. However, we think that this possibility is
extremely unlikely given that the same dose of haloperidol also had
absolutely no effect on T-maze choice accuracy in the wild-type
controls. There is therefore no evidence for any detrimental effects
of haloperidol in terms of choice accuracy memory performance on
the T-maze task.
The fact that haloperidol failed to affect spatial short-term/work-
ing memory in these experiments is in contrast to reports that dopa-
mine receptor blockade can impair reference memory tasks
assessing associative, long-term spatial memory (Whishaw & Dun-
nett, 1985; Ploeger et al., 1992; Gasbarri et al., 1996; Mura & Fel-
don, 2003). We have argued elsewhere that performance on the
win-shift, rewarded alternation, T-maze task likely relies on a
non-associative, short-term memory trace which provides a sense of
relative familiarity based on recent experience (Sanderson & Ban-
nerman, 2012). The present experiments would appear to suggest
that this form of non-associative short-term spatial memory is not
dopamine-dependent.
Conclusions
In summary, the group II mGluR agonist LY354740 and the dopa-
mine D2 receptor antagonist haloperidol reduced the locomotor
hyperactivity seen in Gria1/ mice but had no effect on the spatial
short-term/working memory deﬁcit in these animals. These data sug-
gest that both LY354740 and haloperidol may act by reducing the
expression of behaviour in general, thus silencing any behavioural
phenotype without correcting any underlying deﬁcit in cognition.
This is reminiscent of the clinical situation, in which existing
antipsychotic medications are effective against psychotic symptoms
but have little impact on the cognitive impairments, which are
widely considered to lie at the heart of the disorder (Kahn & Keefe,
2013; Fatouros-Bergman et al., 2014).
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